XXXIII Congreso Nacional de la Sociedad Española de Trombosis y Hemostasia

XXXIII Congreso Nacional de la Sociedad Española de Trombosis y Hemostasia 16 Heritability of plasma concentrations of activated protein C in a Spanish population. Blood Coag Fibrinol 2009;20:17-21. 17. Medina P, Navarro S, Estellés A, Vayá A, Woodhams B, Mira Y, et al. Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circula- ting activated protein C levels and thrombotic risk. Thromb Haemost 2004;91:905-11. 18. Medina P, Navarro S, Estellés A, Vayá A, Bertina RM, España F. Influence of the 4600A/G and 4678G/C polymorphisms in the endothelial protein C receptor (EPCR) gene on the risk of venous thromboembolism in carriers of factor V Leiden. Thromb Haemost 2005;94:389-95. 19. Navarro S, Medina P, Mira Y, Estellés A, Villa P, Ferrando F, et al. Haplotypes of the EPCR gene, prothrombin levels, and the risk of venous thrombosis in carriers of the prothrombin G20210A muta- tion. Haematologica 2008;93:885-91. 20. Medina P, Navarro S, Corral J, Zorio E, Roldán V, Estellés A, et al. Endothelial protein C receptor polymorphisms and risk of myocar- dial infarction. Haematologica 2008;93:1358-63. 21. Medina P, Navarro S, Bonet E, Martos L, Estellés A, Bertina RM, et al. Functional analysis of two haplotypes of the human endothelial protein C receptor gene. Arterioscl Thromb Vasc Biol 2014;34:684-90. 22. Navarro S, Medina P, Bonet E, Corral J, Martínez-Sales V, Martos L, et al. Association of the thrombomodulin gene c.1418C > T poly- morphism with thrombomodulin levels and with venous thrombosis risk. Arterioscl Thromb Vasc Biol 2013;33:1435-40. 23. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, et al. Activated protein C attenuates endotoxin-induced pulmo- nary vascular injury by inhibiting activated leukocytes in rats. Blood 1996;87:642-7. 24. Taylor FB Jr, Chang A, Esmon CT, D’Angelo A, Vigano-D’An- gelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-25. 25. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, López-Rodríguez A, et al . Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709. 26. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008;451:1076-81. 27. Mosnier LO, Gale AJ, Yegneswaran S, Griffin JH. Activated protein C variants with normal cytoprotective but reduced anticoagulant acti- vity. Blood 2004;104:1740-5. 28. Shibata M, Kumar SR, Amar A, Fernández JA, Hofman F, Griffin JH, et al. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 2001;103:1799-805. 29. Liu D, Cheng T, Guo H, Fernández JA, Griffin JH, Song X, et al. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 2004;10:1379-83. 30. Guo H, Liu D, Gelbard H, Cheng T, Insalaco R, Fernández JA, et al. Activated protein C prevents neuronal apoptosis via protease activa- ted receptors 1 and 3. Neuron 2004;41:563-72. 31. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate recep- tor-1 crossactivation. Blood 2005;105:3178-84. 32. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005;131:417-30. 33. Shua F, Kobayashi H, Fukudome K, Tsuneyoshi N, Kimoto M, Terao T. Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner. FEBS Lett 2000;477:208-12. 34. Yuksel M, Okajima K, Uchiba M, Horiuchi S, Okabe H. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis fac- tor-alpha production by inhibiting activation of both nuclear fac- tor-kappa B and activator protein-1 in human monocytes. Thromb Haemost 2002;88:267-73. 35. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007;109:3161-72. 36. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, et al. Activated protein C mediates novel lung endothe- lial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005;280:17286-93.